[1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018; 68: 394-424.
[2] Siegel RL, Miller KD, Jemal A. Cancer statistics. 2019. Cancer J Clin. 2019; 69: 7-34.
[3] Wild CP, Weiderpass E, Stewart BW. World Cancer Report: Cancer Research for Cancer PreventionWorld Cancer Reports 2020
[4] Koshkina NV, Waldrep JC, Roberts LE, Golunski E, Melton S, Knight V. Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin Cancer Res. 2001; 7: 3258-3262.
[5] Ma Z, Li N, Zhang B, Hui YY, Zhang Y, Lu P, et al. Dual drug-loaded nano-platform for targeted cancer therapy: toward clinical therapeutic efficacy of multifunctionality. J Nanobiotechnol. 2020; 18: 123-148.
[6] Erridge SC, Møller H, Price A, Brewster D. International comparisons of survival from lung cancer: pitfalls and warnings. Nat Clin Pract Oncol. 2007; 4:570-577.
[7] Yuan HD, Ma QQ, Li Y, Piao GC. The traditional medicine and modern medicine from natural products. Molecules. 2016;21: 559-577.
[8] Joshi P, Vishwakarma RA, Bharate SB, Natural alkaloids as P-gp inhibitors for multidrug resistance reversal in cancer. Eur J Med Chem. 2017; 138: 273-292.
[9] Li DC, Liu ZH, Liu YF, Zhang QK, Liu C, Zhao SH, et al. Design, synthesis and biological activities of tetrandrine and fangchinoline derivatives as antitumor agents. Bioorg Med Chem Lett. 2017; 27: 533-536.
[10] Lan JJ, Wang N, Huang L, Liu YZ, Ma XP, Lou HY, et al. Design and synthesis of novel tetrandrine derivatives as potential antitumor agents against human hepatocellular carcinoma. Eur J Med Chem. 2017; 127: 554-566.
[11] Yang J, Hu SC, Wang CL, Song JR, Pan WD. Fangchinoline derivatives induce cell cycle arrest and apoptosis in human leukemia cell lines via suppression of the PI3K/AKT and MAPK signaling pathway. Eur J Med Chem. 2020; 186: 111898.
[12] Gong K, Chen C, Zhan Y, Chen Y, Huang Z, Li W. Autophagy related gene7 (ATG7) and reactive oxygen species extracellular signal-regulated kinase regulate tetrandrine induced autophagy in human hepatocellular carcinoma, J Biol Chem. 2012; 287: 35576-35588.
[13] Gao XZ, Lv XT, Zhang RR, Luo Y, Wang MX, Chen JS, et al. Design, synthesis and in vitro anticancer research of novel tetrandrine and fangchinoline derivatives. Bioorg Chem. 2021; 109: 104694
[14] Zhang YC, Gao XZ, Liu C, Wang MX, Zhang RR, Sun JY, et al. Design, synthesis and in vitro evaluation of fangchinoline derivatives as potential anticancer agents. Bioorg Chem. 2020; 94: 103431.
[15] Sarwar B, Ravinder K, Rajneet KK, Vikas R, Teenu S. QbD-Based Development of Cationic Self-nanoemulsifying Drug Delivery Systems of Paclitaxel with Improved Biopharmaceutical Attributes. Pharm. 2019; 20: 118-140.
[16] Feng, L, Mumper, RJ. A critical review of lipid-based nanoparticles for taxane delivery. Cancer Lett. 2013; 334: 157-175.
[17] Sandri G, Motta S, Bonferoni MC, Brocca P, Rossi S, Ferrari F, et al. Chitosancoupled solid lipid nanoparticles: tuning nanostructure and mucoadhesion. Eur J Pharm Biopharm. 2017; 110: 13-18.
[18] Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery a review of the state of the art. Eur J Pharm Biopharm. 2000; 50: 161-177.
[19] Mehnert W, Madex K. Solid lipid nanoparticles: production, characterization and applications, Adv. Drug Deliv Rev. 2001; 47: 165-196.
[20] Ahlin P, Kristl J, Sentjure M. Influence of spin probe structure on its distribution in SLN dispersions, Int. J. Pharm. 2000; 196: 241-244.
[21] Lim SJ, Lee, MK, Kim, CK. Altered chemical and biological activities of alltrans retinoic acid incorporated in solid lipid nanoparticle powders. J Control Release. 2004; 100: 53-61.
[22] Üner, M, Wissing, S, Yener, G, Müller, R. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for application of ascorbyl palmitate. Pharmazie. 2005; 60: 577-582.
[23] Taylor S, Kevin A, Ebony LN, Han B, Felix A, Sunil, Jose T, Edward A. Application of smart solid lipid nanoparticles to enhance the efcacy of 5-fuorouracil in the treatment of colorectal cancer. Scientifc Rep. 2020; 10: 16989.
[24] Mahfoozur R, Waleed H A, Obaid A, Abdulmalik SA, Imran K, Fahad A, et al. Cationic solid lipid nanoparticles of resveratrol for hepatocellular carcinoma treatment: systematic optimization, in vitro characterization and preclinical Investigation. Int J Nanomedicine. 2020; 15: 9283-9299.
[25] Ali R, Rassoul D, Behrooz J, Saeedeh JN, Ali R, Elham R, et al. Preparation and investigation of indirubin-loaded SLN nanoparticles and their anti-cancer effects on human glioblastoma U87MG cells. Cell Biol Int. 2019; 43: 2-11.
[26] Kaur IP, Bhandari R, Bhandari S, Kakkar V. Potential of solid lipid nanoparticles in brain targeting. J Control Release. 2008; 127: 97-109.
[27] Neves AR, Queiroz JF, Sofia A, Lima C, Figueiredo F, Fernandes R, et al. Cellular uptake and transcytosis of lipid-based nanoparticles across theintestinal barrier: relevance for oral drug delivery. J Colloid Interface. 2016; 463: 258-265.
[28] Wong HL, Chattopadhyay N, Wu XY, Bendayan R. Nanotechnology applications for improved delivery of antiretroviral drugs to the brain. Adv Drug Deliv Rev. 2010; 62: 503-517.
[29] Neves AR, Lucio M, Martins S, Lima JL, Reis S. Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability. Int J Nanomedicine. 2013; 8: 177-187.
[30] Rahman Z, Zidan AS, Khan MA. Non-destructive methods of characterization of risperidone solid lipid nanoparticles. Eur J Pharm Biopharm. 2010; 76: 127-137.
[31] Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery. II. Drug incorporation and physicochemical characterization. J Microencapsul. 1999; 16: 205-213.
[32] Ma L, Yang DW, Li ZX, Zhang X, Pu L. Co-delivery of paclitaxel and tanespimycin in lipid nanoparticles enhanced anti-gastric-tumor effect in vitro and in vivo. Artif Cell NAanomed B. 2018; 46: 904-911.
[33] Anton N, Benoit JP, Saulnier P. Design and production of nanoparticles formulated from nano-emulsion templates-a review. J Control Release. 2008; 128: 185-199.
[34] Estella HM, Rayo M, Mollinedo F, Blanco MJ. Lipid nanoparticles for alkyl lysophospholipid edelfosine encapsulation: development and in vitro characterization. Eur J Pharm Biopharm. 2008; 68: 207-213.
[35] Semete B, Booysen LJ, Kalombo L, Venter JD, Katata L, Ramalapa B, et al. In vivo uptake and acute immune response to orally administeredchitosan and PEG coated PLGA nanoparticles. Toxicol Appl Pharmacol. 2010; 249: 158-165.
[36] Bhatt H, Rompicharla SK, Komanduri N, et al. Development of curcumin loaded solid lipid nanoparticles utilizing glyceryl monostearate as single lipid using QbD approach: characterization and evaluation of anticancer activity against human breast cancer cell line. Curr Drug Deliv. 2018; 15: 1271-1283.
[37] Márcia CR, Patrícia BS, Marina AR, Bárbara YG, Jaqueline VO, Tom V, et al. Docetaxel-loaded solid lipid nanoparticles prevent tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells. J Nanobiotechnol. 2020; 18: 43-52.
[38] Liu Y, Pan J, Feng SS. Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance. Int J Pharm. 2010; 395: 243-250.
[39] Jain A, Thakur K, Kush P, Jain UK. Docetaxel loaded chitosan nanoparticles:formulation, characterization and cytotoxicity studies. Int J Biol Macromol. 2014; 69: 546-553.
[40] Kaur S, Nautyal U, Singh R, Singh S, Devi A. Nanostructure lipid carrier (NLC): the new generation of lipid nanoparticles. Asian Pac J Health. 2015; 2: 76-93.
[41] Feng SS, Mei L, Anitha P, Gan CW, Zhou W. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel. Biomaterials. 2009; 30: 3297-3306.
[42] Naguib YW, Rodriguez BL, Li X, Hursting SD, Williams RO, Cui Z. Solid lipid nanoparticle formulations of docetaxel prepared with high melting point triglycerides: in vitro and in vivo evaluation. Mol Pharm. 2014; 11: 1239-1249.
[43] Padhye SG, Nagarsenker MS. Simvastatin solid lipid nanoparticles for oraldelivery: formulation development and in vivo evaluation. Indian J Pharm. 2013; 75: 591-598.
[44] Ana RN, Joana FQ, Salette R. Brain-targeted delivery of resveratrol using solid lipid nanoparticles functionalized with apolipoprotein. J Nanobiotechnol. 2016; 14: 27.
[45] Long JT, Chang TY, Zhuo SY. Anticancer drug-loaded multifunctional nanoparticles to enhance the chemotherapeutic efficacy in lung cancer metastasis. J Nanobiotechnol. 2014; 12: 37.
[46] Valdes SA, Alzhrani RF, Rodriguez A, Lansakara DP, Thakkar SG, Cui ZR. A solid lipid nanoparticle formulation of 4-(N)-docosahexaenoyl 2’,2’- difluorodeoxycytidine with increased solubility, stability, and antitumoractivity. Int J Pharm. 2019; 570: 118609.
[47] Bao NT, Hanh TN, Jong OK, Chul SY, Chien NN. Combination of a chemopreventive agent and paclitaxel in CD44-targeted hybrid nanoparticles for breast cancer treatment. Arch Pharm Res. 2017; 40: 1420-1432.
[48] Sánchez MP, Boulaiz H, Ortega JL, Peula JM, Aránega A. Novel drug delivery system based on docetaxel loaded nanocapsules as a therapeutic strategy against breast cancer cells. Int J Mol. 2012; 13: 4906-4919.
[49] Patel J, Amrutiya J, Bhatt P, Javia A, Jain M, Misra A. Targeted delivery of monoclonal antibody conjugated docetaxel loaded PLGA nanoparticles into EGFR overexpressed lung tumour cells. J Microencapsul. 2018; 35: 204-217.
[50] Jiang FQ, Ren S, Chen YD, Zhang A, Zhu YK, Zhang ZN. Fangchinoline exerts antitumour activity by suppressing the EGFR-PI3K/AKT signalling pathway in colon adenocarcinoma. Oncol Rep. 2020; 45: 139-150.
[51] Xing ZB, Lei YA, Zhang GQ, Zhang XY. Fangchinoline inhibits breast adenocarcinoma proliferation by inducing apoptosis. Chem Pharm Bull. 2011; 59: 1476-1480.
[52] Vaishali MG, Shital MS, Makarand SG. Atorvastatin loaded lipid nanoparticles: Antitumor Drug Development and Industrial Pharmacy activity studies on MCF-7 breast cancer cells. Drug Dev Ind Pharm. 2018; 44: 1-37.
[53] Xiong J, Wang D, Wei A, Lu A. Deregulated expression of miR-107 inhibits metastasis of PDAC through inhibition PI3K/AKT signaling via caveolin-1 and PTEN. Exp Cell Res. 2017; 361: 316-323.
[54] Lei B, Sun S, Zhang X. Bisphenol AF exerts estrogenic activity in MCF-7 cells through activation of Erk and PI3K/AKT signals via GPER signaling pathway. Chemos. 2019; 220: 362-370.
[55] Grille SJ, Bellacosa A, Upson J. The protein kinase AKT induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Can Res. 2003; 63: 2172-2178.